Physician profile
John A Greer
NPI 1356393227
$7,646.30
in general payments reported to CMS, 2019-2025
31 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $92.74 · 2021: $5,859 · 2022: $444 · 2023: $497 · 2024: $334 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.12 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $5,012.36 | 2021-2022 | |
| Sn Holdings, LLC | $917.41 | 2021-2023 | |
| Abbvie INC. | $270.20 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $233.49 | 2019-2025 | |
| Urogpo LLC | $196.26 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $170.48 | 2023-2024 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $117.57 | 2019-2023 | Xtandi |
| Merck Sharp & Dohme LLC | $84.04 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Boston Scientific Corporation | $83.85 | 2022-2023 | Lithovue |
| Pfizer INC. | $75.06 | 2022-2024 | |
| Janssen Biotech, INC. | $73.01 | 2019-2024 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $52.25 | 2023-2024 | Provenge |
| Janssen Pharmaceuticals, INC | $38.00 | 2019 | |
| Urogen Pharma, INC. | $35.90 | 2022 | |
| Teleflex LLC | $32.37 | 2023 | Urolift |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $30.20 | 2024 | |
| Amgen INC. | $23.54 | 2022 | |
| Allergan, INC. | $22.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $20.34 | 2022 | |
| Bioprotect Medical, INC. | $18.93 | 2025 | Bioprotect Balloon Implant System |
| Accord Healthcare, INC. | $18.49 | 2023 | |
| Telix Pharmaceuticals | $16.80 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.75 | 2025 | Adstiladrin |
| Foundation Medicine, INC. | $15.54 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $14.43 | 2022 | |
| Endo Pharmaceuticals INC. | $13.95 | 2022 | |
| Sun Pharmaceutical Industries INC. | $13.70 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.09 | 2023 | Lynparza |
| Urovant Sciences INC | $13.02 | 2022 | |
| Travere Therapeutics, INC. | $3.82 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$484,622.74 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.